KYNB
Kyntra Bio, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Kyntra Bio has 6 disclosed suppliers and 5 disclosed customers in SEC filings.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Expected move
No implied move.
SentenceWe currently rely, and expect to continue to rely, on third parties to scale-up, manufacture and supply roxadustat and our other product candidates for drug product in Europe and other countries, and on our partner Astellas for drug product in Japan.
KYNB 10-Kaccession 0001193125-26-108346
SentenceWe have entered into an Evaluation Agreement with Fortis Therapeutics, Inc. ("Fortis") under which we rely, in part, on Fortis and its development partners, including University of California, San Francisco, for the continued development of FG-3246 (in conjunction with our PET biomarker).
KYNB 10-Kaccession 0001193125-26-108346
SentenceShanghai SynTheAll Pharmaceutical Co., Ltd. ("WuXi STA"), our supplier of roxadustat drug substance, is also included in this legislation since it is a branch of WuXi Apptec.
KYNB 10-Kaccession 0001193125-26-108346
SentenceWe have entered into an Evaluation Agreement with Fortis Therapeutics, Inc. ("Fortis") under which we rely, in part, on Fortis and its development partners, including University of California, San Francisco, for the continued development of FG-3246 (in conjunction with our PET biomarker).
KYNB 10-Kaccession 0001193125-26-108346
SentenceThis can impact the FG-3246 program as we source the linker and payload from WuXi STA and we manufacture antibody, antibody drug conjugate drug substance and antibody drug conjugate drug product at WuXi Biologics and WuXi XDC.
KYNB 10-Kaccession 0001193125-26-108346
SentenceThis can impact the FG-3246 program as we source the linker and payload from WuXi STA and we manufacture antibody, antibody drug conjugate drug substance and antibody drug conjugate drug product at WuXi Biologics and WuXi XDC.
KYNB 10-Kaccession 0001193125-26-108346
SentenceIn 2020, we entered into a Master Supply Agreement with AstraZeneca under the AstraZeneca U.S./RoW Agreement (the "AstraZeneca Master Supply Agreement") to define general forecast, order, supply and payment terms for AstraZeneca to purchase roxadustat bulk drug product from Kyntra Bio in support of commercial supplies.
SentenceOur revenue for the year ended December 31, 2025 primarily included $5.8 million of drug product revenue from commercial-grade active pharmaceutical ingredient ("API") or bulk drug product sales to Astellas.
KYNB 10-Kaccession 0001193125-26-108346
SentenceAs disclosed in our Current Report on Form 8‑K filed in February 20, 2025, we agreed to two holdback amounts from the consideration paid by AstraZeneca Treasury Limited (the "AZ Holdbacks") in connection with the sale of FibroGen International and its subsidiaries.
KYNB 10-Kaccession 0001193125-26-108346
SentenceDuring the years ended December 31, 2025 and 2024, included in the discontinued operations, we recognized $218.6 million and $159.0 million of net product revenue from the sales to Falikang, and $8.1 million and $14.7 million of net product revenue from sales directly to distributors in one province in China, respectively.
KYNB 10-Kaccession 0001193125-26-108346
SentenceIn April 2023, we entered into an Amended and Restated Exclusive License Agreement with Eluminex ("A&R Eluminex Agreement") in order to add to the license rights to recombinant human collagen Type I (in addition to the rights to collagen Type III that were already licensed).
KYNB 10-Kaccession 0001193125-26-108346
Kyntra Bio, Inc.
4.64
−0.01 · −0.20%
post 4.69 +1.06%
Linked news
News